Lieber Carsten, wir wünschen viel Erfolg bei Deiner neuen Aufgabe!
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces completion of recruitment of its commercial management team in Europe and its intention to promote and appoint three executive officers in support of planned commercial European launch and international expansion of its lead product, NexoBrid(R) , as well as its research and development efforts.
MediWound announces its intention to promote Mr. Carsten Henke to Chief Commercial Officer, Europe. Mr. Henke, 48, who has served as Managing Director of MediWound Germany GmbH since July 2013, will be promoted to Chief Commercial Officer, Europe. From February 2009 to December 2012, Mr. Henke served as Teva Pharmaceutical Industries Ltd. General Manager in Spain, and from January 2004 to January 2009, he served as Teva's Director of Marketing and Sales in Germany. At Teva he established various sales and marketing organizations and successfully launched and marketed pharmaceutical products. With more than two decades of experience in sales and marketing in Europe, Mr. Henke has held numerous commercial roles at Teva, EMD Serono, Sanofi S.A. and the Merck Group.
Mr. Henke holds a B.Sc. in European Management from the ESB Business School at Reutlingen University and a Graduado Superior in International Business Administration--E-4 from Comillas Pontifical University ICAI--ICADE in Madrid, Spain.
In addition to his current responsibilities in Germany, Mr. Henke will oversee MediWound's commercialization efforts in Europe and will lead and manage the local Business Managers throughout Europe.